The US biotech and pharmaceutical landscape faces significant regulatory changes and political pressures. An executive order from the Trump administration aims to increase domestic pharmaceutical manufacturing through streamlined FDA programs like PreCheck, which expedites review for new drug facilities. Concurrently, political interference in science funding is intensifying, with orders directing agency leadership to align grant reviews with presidential priorities. Additionally, concerns over drug pricing have led to new industry coalitions opposing Medicare price negotiations, while Eli Lilly's pricing strategies draw scrutiny and legal challenges, underscoring the tension between innovation incentives and affordability.